These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 12771471)

  • 1. Intramuscular alefacept improves health-related quality of life in patients with chronic plaque psoriasis.
    Finlay AY; Salek MS; Haney J;
    Dermatology; 2003; 206(4):307-15. PubMed ID: 12771471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of alefacept on health-related quality of life in patients with psoriasis: results from a randomized, placebo-controlled phase II trial.
    Ellis CN; Mordin MM; Adler EY;
    Am J Clin Dermatol; 2003; 4(2):131-9. PubMed ID: 12553852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved health-related quality of life following a randomized controlled trial of alefacept treatment in patients with chronic plaque psoriasis.
    Feldman SR; Menter A; Koo JY
    Br J Dermatol; 2004 Feb; 150(2):317-26. PubMed ID: 14996104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis.
    Lebwohl M; Christophers E; Langley R; Ortonne JP; Roberts J; Griffiths CE;
    Arch Dermatol; 2003 Jun; 139(6):719-27. PubMed ID: 12810502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alefacept.
    Frampton J; Wagstaff A
    Am J Clin Dermatol; 2003; 4(4):277-86; discussion 287. PubMed ID: 12680805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ISA247: quality of life results from a phase II, randomized, placebo-controlled study.
    Gupta AK; Langley RG; Lynde C; Barber K; Gulliver W; Lauzon G; Aspeslet LJ; Foster RT; Huizinga RB; Yatscoff RW
    J Cutan Med Surg; 2008; 12(6):268-75. PubMed ID: 19317948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The AWARE study: methodology and baseline characteristics.
    Bissonnette R; Searles G; Landells I; Shear NH; Papp K; Lui H; Gulliver WP; Lynde C
    J Cutan Med Surg; 2009 Dec; 13 Suppl 3():S113-21. PubMed ID: 20053323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial.
    Krueger GG; Langley RG; Finlay AY; Griffiths CE; Woolley JM; Lalla D; Jahreis A
    Br J Dermatol; 2005 Dec; 153(6):1192-9. PubMed ID: 16307657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of efalizumab on patient-reported outcomes in high-need psoriasis patients: results of the international, randomized, placebo-controlled Phase III Clinical Experience Acquired with Raptiva (CLEAR) trial [NCT00256139].
    Ortonne JP; Shear N; Shumack S; Henninger E;
    BMC Dermatol; 2005 Dec; 5():13. PubMed ID: 16359548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alefacept: a novel biologic in the treatment of psoriasis.
    Liu CM; McKenna JK; Krueger GG
    Drugs Today (Barc); 2004 Dec; 40(12):961-74. PubMed ID: 15645008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study.
    Shikiar R; Willian MK; Okun MM; Thompson CS; Revicki DA
    Health Qual Life Outcomes; 2006 Sep; 4():71. PubMed ID: 17005043
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of palmoplantar psoriasis with intramuscular alefacept.
    Myers W; Christiansen L; Gottlieb AB
    J Am Acad Dermatol; 2005 Aug; 53(2 Suppl 1):S127-9. PubMed ID: 16021161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial.
    Reich K; Nestle FO; Papp K; Ortonne JP; Wu Y; Bala M; Evans R; Guzzo C; Li S; Dooley LT; Griffiths CE
    Br J Dermatol; 2006 Jun; 154(6):1161-8. PubMed ID: 16704649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quality of life and cost of illness in patients with psoriasis in Malaysia: a multicenter study.
    Tang MM; Chang CC; Chan LC; Heng A
    Int J Dermatol; 2013 Mar; 52(3):314-22. PubMed ID: 23414155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Dermatology Life Quality Index: assessing the efficacy of biological therapies for psoriasis.
    Katugampola RP; Lewis VJ; Finlay AY
    Br J Dermatol; 2007 May; 156(5):945-50. PubMed ID: 17388922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Explorative immunohistochemical study to evaluate the addition of a topical corticosteroid in the early phase of alefacept treatment for psoriasis.
    Bovenschen HJ; Gerritsen WJ; van Rens DW; Seyger MM; de Jong EM; van de Kerkhof PC
    Arch Dermatol Res; 2007 Feb; 298(9):457-63. PubMed ID: 17136563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of psoriasis on patients' quality of life and improvements associated with alefacept therapy.
    Menter A
    J Cutan Med Surg; 2004 Dec; 8 Suppl 2():20-5. PubMed ID: 15668752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alefacept in the treatment of psoriasis in patients for whom conventional therapies are inadequate.
    van de Kerkhof P; Griffiths CE; Christophers E; Lebwohl M; Krueger GG
    Dermatology; 2005; 211(3):256-63. PubMed ID: 16205071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial.
    Feldman SR; Gordon KB; Bala M; Evans R; Li S; Dooley LT; Guzzo C; Patel K; Menter A; Gottlieb AB
    Br J Dermatol; 2005 May; 152(5):954-60. PubMed ID: 15888152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adalimumab treatment is associated with improvement in health-related quality of life in psoriasis: patient-reported outcomes from a phase II randomized controlled trial.
    Shikiar R; Heffernan M; Langley RG; Willian MK; Okun MM; Revicki DA
    J Dermatolog Treat; 2007; 18(1):25-31. PubMed ID: 17365264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.